Viewing nowCombinationTelotatin Tablets 80/5/10 mg
Telmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.

MFDS item code 202004763 · Approved 2020.06.30 · Insurance code 649508020
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
This medication is administered to patients with essential hypertension who have difficulty in controlling blood pressure using a combination of telmisartan and amlodipine. Additionally, rosuvastatin is used as an adjunct treatment when dietary therapy and other baseline treatments are insufficient for hypercholesterolemia and familial hypercholesterolemia. This medication helps improve lipid levels in patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia, and slows the progression of atherosclerosis. In elderly patients at high cardiovascular risk, a reduction in risks of stroke, myocardial infarction, and vascular revascularization is also expected. Therefore, this medication is effectively used to treat essential hypertension and hypercholesterolemia.
Take 1 tablet once daily with water, regardless of meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, switching to this medicine (a combination product with the same amounts of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: Dose adjustment is not required in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.1-fold and AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.
This medication should not be used in pregnant women, and if pregnancy is confirmed, administration must be stopped immediately due to serious risks to the fetus and newborn. Patients with hypersensitivity to this medication, certain genetic disorders, severe liver disease, kidney disease, or myopathy should not use it. Caution is advised for the elderly or patients with hypotension, hyperkalemia, or liver disease, especially if muscle pain or weakness symptoms occur, in which case a physician should be consulted immediately. Since this medication may cause muscle-related side effects, it is crucial to regularly check muscle enzyme levels before and during treatment. If severe muscle pain or weakness occurs, the medication may need to be discontinued. Liver function tests are recommended before and during treatment due to potential liver dysfunction. If liver enzyme levels rise significantly, the medication should be discontinued. This medication may interact with several other drugs, so inform your physician or pharmacist of any other medications you are taking. Nursing mothers are advised not to take this medication, and if unavoidable, should discontinue breastfeeding. It is not recommended for children and adolescents under 18 years of age as safety and efficacy have not been established. In cases of overdose, symptoms such as hypotension and cardiac arrhythmias may occur, so it is essential to contact a medical facility immediately for appropriate treatment. Keep this medication out of reach of children, and do not transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that protects it from light, maintaining a storage temperature between 1 to 30 degrees Celsius. Proper storage will help retain the effectiveness and safety of the medication.
An oval biconvex bilayer tablet consisting of a white layer and a light blue layer
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Myeong Mun Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Samchundang Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.